Truist raised the firm’s price target on Pediatrix Medical to $10 from $8 and keeps a Hold rating on the shares. The firm is adjusting its estimates to reflect the company’s Q2 earnings beat, also raising its FY24 adjusted EBITDA view by $7M to $208M and its FY25 view by $10M to $218M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Announces Executive Shakeup and New CFO Appointment
- Pediatrix Medical still sees 2024 adjusted EBITDA $200M-$220M
- Pediatrix Medical reports Q2 adjusted EPS 34c, consensus 31c
- MD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pediatrix Medical price target lowered to $8 from $10 at Truist